As an EGFR over-expression cancer, locally advanced NSCLC has been treated with concurrent chemo-radiation with a 5-year survival of approximately 15%, and 5 year loco-regional control of approximately 70% based on major randomized studies [49]. The gene discussed is EGFR; the disease is cancer.